−1.82HKD
−796.57 MHKD
542.97 MHKD
285.53 M
About VENUS MEDTECH (HANGZHOU) INC
Sector
Industry
CEO
Hou-Sen Lim
Website
Headquarters
Wanchai
Employees (FY)
865
Founded
2009
ISIN
CNE100003PJ8
FIGI
BBG00QTMSFW3
Venus Medtech (Hangzhou), Inc. provides transcatheter heart valve medical device. It engages in the research and development of cardiac intervention system for heart diseases. The company offers pre-implanted invasive heart valve systems such as transcatheter artery and pulmonary artery valve systems, and delivery catheter systems. The company was founded on July 3, 2009 and is headquartered in Hangzhou, China.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 2500 is 5.62 HKD — it has decreased by 0.71% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange VENUS MEDTECH (HANGZHOU) INC stocks are traded under the ticker 2500.
VENUS MEDTECH (HANGZHOU) INC is going to release the next earnings report on Aug 29, 2024. Keep track of upcoming events with our Earnings Calendar.
2500 stock is 8.00% volatile and has beta coefficient of 2.04. Check out the list of the most volatile stocks — is VENUS MEDTECH (HANGZHOU) INC there?
2500 earnings for the last quarter are −0.86 HKD per share, whereas the estimation was −0.72 HKD resulting in a −19.40% surprise. The estimated earnings for the next quarter are −0.65 HKD per share. See more details about VENUS MEDTECH (HANGZHOU) INC earnings.
VENUS MEDTECH (HANGZHOU) INC revenue for the last quarter amounts to 276.23 M HKD despite the estimated figure of 273.32 M HKD. In the next quarter revenue is expected to reach 285.77 M HKD.
Yes, you can track VENUS MEDTECH (HANGZHOU) INC financials in yearly and quarterly reports right on TradingView.
2500 net income for the last quarter is −400.47 M HKD, while the quarter before that showed −396.05 M HKD of net income which accounts for −1.12% change. Track more VENUS MEDTECH (HANGZHOU) INC financial stats to get the full picture.
Today VENUS MEDTECH (HANGZHOU) INC has the market capitalization of 2.46 B, it has increased by 10.20% over the last week.
No, 2500 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 2500 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VENUS MEDTECH (HANGZHOU) INC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 865.00 employees. See our rating of the largest employees — is VENUS MEDTECH (HANGZHOU) INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VENUS MEDTECH (HANGZHOU) INC technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VENUS MEDTECH (HANGZHOU) INC stock shows the neutral signal. See more of VENUS MEDTECH (HANGZHOU) INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on VENUS MEDTECH (HANGZHOU) INC future price: according to them, 2500 price has a max estimate of 6.00 HKD and a min estimate of 6.00 HKD. Read a more detailed VENUS MEDTECH (HANGZHOU) INC forecast: see what analysts think of VENUS MEDTECH (HANGZHOU) INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VENUS MEDTECH (HANGZHOU) INC EBITDA is −521.79 M HKD, and current EBITDA margin is −95.60%. See more stats in VENUS MEDTECH (HANGZHOU) INC financial statements.